Search Results - "Vokes, Natalie"

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma by Bi, Kevin, He, Meng Xiao, Bakouny, Ziad, Kanodia, Abhay, Napolitano, Sara, Wu, Jingyi, Grimaldi, Grace, Braun, David A., Cuoco, Michael S., Mayorga, Angie, DelloStritto, Laura, Bouchard, Gabrielle, Steinharter, John, Tewari, Alok K., Vokes, Natalie I., Shannon, Erin, Sun, Maxine, Park, Jihye, Chang, Steven L., McGregor, Bradley A., Haq, Rizwan, Denize, Thomas, Signoretti, Sabina, Guerriero, Jennifer L., Vigneau, Sébastien, Rozenblatt-Rosen, Orit, Rotem, Asaf, Regev, Aviv, Choueiri, Toni K., Van Allen, Eliezer M.

“…Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients with advanced renal cell carcinoma (RCC), but mechanisms driving…”
Get full text

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities by Gay, Carl M., Stewart, C. Allison, Park, Elizabeth M., Diao, Lixia, Groves, Sarah M., Heeke, Simon, Nabet, Barzin Y., Fujimoto, Junya, Solis, Luisa M., Lu, Wei, Xi, Yuanxin, Cardnell, Robert J., Wang, Qi, Fabbri, Giulia, Cargill, Kasey R., Vokes, Natalie I., Ramkumar, Kavya, Zhang, Bingnan, Della Corte, Carminia M., Robson, Paul, Swisher, Stephen G., Roth, Jack A., Glisson, Bonnie S., Shames, David S., Wistuba, Ignacio I., Wang, Jing, Quaranta, Vito, Minna, John, Heymach, John V., Byers, Lauren Averett

“…Despite molecular and clinical heterogeneity, small cell lung cancer (SCLC) is treated as a single entity with predictably poor results. Using tumor expression…”
Get full text

Tracing Compartmentalized NADPH Metabolism in the Cytosol and Mitochondria of Mammalian Cells by Lewis, Caroline A., Parker, Seth J., Fiske, Brian P., McCloskey, Douglas, Gui, Dan Y., Green, Courtney R., Vokes, Natalie I., Feist, Adam M., Vander Heiden, Matthew G., Metallo, Christian M.

“…Eukaryotic cells compartmentalize biochemical processes in different organelles, often relying on metabolic cycles to shuttle reducing equivalents across…”
Get full text

Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma by Vokes, Natalie I, Chambers, Emily, Nguyen, Tom, Coolidge, Alexis, Lydon, Christine A, Le, Xiuning, Sholl, Lynette, Heymach, John V, Nishino, Mizuki, Van Allen, Eliezer M, Jänne, Pasi A

“…Patients with EGFR-mutant NSCLC experience variable duration of benefit on EGFR tyrosine kinase inhibitors. The effect of concurrent genomic alterations on…”
Get more information

PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC by Vokes, Natalie I, Le, Xiuning, Yap, Timothy A

“…A recent study identified high rates of PI3K-AKT pathway mutations from the FLAURA and AURA3 osimertinib trials and pre-clinically validated that these…”
Get full text

Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels by Ricciuti, Biagio, Wang, Xinan, Alessi, Joao V, Rizvi, Hira, Mahadevan, Navin R, Li, Yvonne Y, Polio, Andrew, Lindsay, James, Umeton, Renato, Sinha, Rileen, Vokes, Natalie I, Recondo, Gonzalo, Lamberti, Giuseppe, Lawrence, Marissa, Vaz, Victor R, Leonardi, Giulia C, Plodkowski, Andrew J, Gupta, Hersh, Cherniack, Andrew D, Tolstorukov, Michael Y, Sharma, Bijaya, Felt, Kristen D, Gainor, Justin F, Ravi, Arvind, Getz, Gad, Schalper, Kurt A, Henick, Brian, Forde, Patrick, Anagnostou, Valsamo, Jänne, Pasi A, Van Allen, Eliezer M, Nishino, Mizuki, Sholl, Lynette M, Christiani, David C, Lin, Xihong, Rodig, Scott J, Hellmann, Matthew D, Awad, Mark M

“…Although tumor mutation burden (TMB) has been explored as a potential biomarker of immunotherapy efficacy in solid tumors, there still is a lack of consensus…”
Get more information

Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors by Miao, Diana, Margolis, Claire A., Vokes, Natalie I., Liu, David, Taylor-Weiner, Amaro, Wankowicz, Stephanie M., Adeegbe, Dennis, Keliher, Daniel, Schilling, Bastian, Tracy, Adam, Manos, Michael, Chau, Nicole G., Hanna, Glenn J., Polak, Paz, Rodig, Scott J., Signoretti, Sabina, Sholl, Lynette M., Engelman, Jeffrey A., Getz, Gad, Jänne, Pasi A., Haddad, Robert I., Choueiri, Toni K., Barbie, David A., Haq, Rizwan, Awad, Mark M., Schadendorf, Dirk, Hodi, F. Stephen, Bellmunt, Joaquim, Wong, Kwok-Kin, Hammerman, Peter, Van Allen, Eliezer M.

“…Tumor mutational burden correlates with response to immune checkpoint blockade in multiple solid tumors, although in microsatellite-stable tumors this…”
Get full text

Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer by Vokes, Natalie I., Pan, Kelsey, Le, Xiuning

“…For advanced metastatic non-small-lung cancer, the landscape of actionable driver alterations is rapidly growing, with nine targetable oncogenes and seven…”
Get full text

Machine Learning Models for the Identification of Prognostic and Predictive Cancer Biomarkers: A Systematic Review by Al-Tashi, Qasem, Saad, Maliazurina B, Muneer, Amgad, Qureshi, Rizwan, Mirjalili, Seyedali, Sheshadri, Ajay, Le, Xiuning, Vokes, Natalie I, Zhang, Jianjun, Wu, Jia

“…The identification of biomarkers plays a crucial role in personalized medicine, both in the clinical and research settings. However, the contrast between…”
Get full text

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status by Ricciuti, Biagio, Arbour, Kathryn C, Lin, Jessica J, Vajdi, Amir, Vokes, Natalie, Hong, Lingzhi, Zhang, Jianjun, Tolstorukov, Michael Y, Li, Yvonne Y, Spurr, Liam F, Cherniack, Andrew D, Recondo, Gonzalo, Lamberti, Giuseppe, Wang, Xinan, Venkatraman, Deepti, Alessi, Joao V, Vaz, Victor R, Rizvi, Hira, Egger, Jacklynn, Plodkowski, Andrew J, Khosrowjerdi, Sara, Digumarthy, Subba, Park, Hyesun, Vaz, Nuno, Nishino, Mizuki, Sholl, Lynette M, Barbie, David, Altan, Mehmet, Heymach, John V, Skoulidis, Ferdinandos, Gainor, Justin F, Hellmann, Matthew D, Awad, Mark M

“…STK11 and KEAP1 mutations (STK11 mutant [STK11 ] and KEAP1 ) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11 has been…”
Get more information

Transcriptional mediators of treatment resistance in lethal prostate cancer by He, Meng Xiao, Cuoco, Michael S., Crowdis, Jett, Bosma-Moody, Alice, Zhang, Zhenwei, Bi, Kevin, Kanodia, Abhay, Su, Mei-Ju, Ku, Sheng-Yu, Garcia, Maria Mica, Sweet, Amalia R., Rodman, Christopher, DelloStritto, Laura, Silver, Rebecca, Steinharter, John, Shah, Parin, Izar, Benjamin, Walk, Nathan C., Burke, Kelly P., Bakouny, Ziad, Tewari, Alok K., Liu, David, Camp, Sabrina Y., Vokes, Natalie I., Salari, Keyan, Park, Jihye, Vigneau, Sébastien, Fong, Lawrence, Russo, Joshua W., Yuan, Xin, Balk, Steven P., Beltran, Himisha, Rozenblatt-Rosen, Orit, Regev, Aviv, Rotem, Asaf, Taplin, Mary-Ellen, Van Allen, Eliezer M.

“…Metastatic castration-resistant prostate cancer is typically lethal, exhibiting intrinsic or acquired resistance to second-generation androgen-targeting…”
Get full text

Reductive glutamine metabolism is a function of the α-ketoglutarate to citrate ratio in cells by Fendt, Sarah-Maria, Bell, Eric L., Keibler, Mark A., Olenchock, Benjamin A., Mayers, Jared R., Wasylenko, Thomas M., Vokes, Natalie I., Guarente, Leonard, Heiden, Matthew G. Vander, Stephanopoulos, Gregory

“…Reductively metabolized glutamine is a major cellular carbon source for fatty acid synthesis during hypoxia or when mitochondrial respiration is impaired. Yet,…”
Get full text

Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis by Locasale, Jason W, Cantley, Lewis C, Vander Heiden, Matthew G, Grassian, Alexandra R, Melman, Tamar, Lyssiotis, Costas A, Mattaini, Katherine R, Bass, Adam J, Heffron, Gregory, Metallo, Christian M, Muranen, Taru, Sharfi, Hadar, Sasaki, Atsuo T, Anastasiou, Dimitrios, Mullarky, Edouard, Vokes, Natalie I, Sasaki, Mika, Beroukhim, Rameen, Stephanopoulos, Gregory, Ligon, Azra H, Meyerson, Matthew, Richardson, Andrea L, Chin, Lynda, Wagner, Gerhard, Asara, John M, Brugge, Joan S

“…Most tumors exhibit increased glucose metabolism to lactate, however, the extent to which glucose-derived metabolic fluxes are used for alternative processes…”
Get full text

MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma by Qian, Yu, Galan-Cobo, Ana, Guijarro, Irene, Dang, Minghao, Molkentine, David, Poteete, Alissa, Zhang, Fahao, Wang, Qi, Wang, Jing, Parra, Edwin, Panda, Apekshya, Fang, Jacy, Skoulidis, Ferdinandos, Wistuba, Ignacio I., Verma, Svena, Merghoub, Taha, Wolchok, Jedd D., Wong, Kwok-Kin, DeBerardinis, Ralph J., Minna, John D., Vokes, Natalie I., Meador, Catherine B., Gainor, Justin F., Wang, Linghua, Reuben, Alexandre, Heymach, John V.

“…Inactivating STK11/LKB1 mutations are genomic drivers of primary resistance to immunotherapy in KRAS-mutated lung adenocarcinoma (LUAD), although the…”
Get full text

Integrative clinical and molecular characterization of translocation renal cell carcinoma by Bakouny, Ziad, Sadagopan, Ananthan, Ravi, Praful, Metaferia, Nebiyou Y, Li, Jiao, AbuHammad, Shatha, Tang, Stephen, Denize, Thomas, Garner, Emma R, Gao, Xin, Braun, David A, Hirsch, Laure, Steinharter, John A, Bouchard, Gabrielle, Walton, Emily, West, Destiny, Labaki, Chris, Dudani, Shaan, Gan, Chun-Loo, Sethunath, Vidyalakshmi, Carvalho, Filipe L F, Imamovic, Alma, Ricker, Cora, Vokes, Natalie I, Nyman, Jackson, Berchuck, Jacob E, Park, Jihye, Hirsch, Michelle S, Haq, Rizwan, Mary Lee, Gwo-Shu, McGregor, Bradley A, Chang, Steven L, Feldman, Adam S, Wu, Catherine J, McDermott, David F, Heng, Daniel Y C, Signoretti, Sabina, Van Allen, Eliezer M, Choueiri, Toni K, Viswanathan, Srinivas R

“…Translocation renal cell carcinoma (tRCC) is a poorly characterized subtype of kidney cancer driven by MiT/TFE gene fusions. Here, we define the landmarks of…”
Get full text

Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer by Hong, Lingzhi, Aminu, Muhammad, Li, Shenduo, Lu, Xuetao, Petranovic, Milena, Saad, Maliazurina B., Chen, Pingjun, Qin, Kang, Varghese, Susan, Rinsurongkawong, Waree, Rinsurongkawong, Vadeerat, Spelman, Amy, Elamin, Yasir Y., Negrao, Marcelo V., Skoulidis, Ferdinandos, Gay, Carl M., Cascone, Tina, Gandhi, Saumil J., Lin, Steven H., Lee, Percy P., Carter, Brett W., Wu, Carol C., Antonoff, Mara B., Sepesi, Boris, Lewis, Jeff, Gibbons, Don L., Vaporciyan, Ara A., Le, Xiuning, Jack Lee, J., Roy-Chowdhuri, Sinchita, Routbort, Mark J., Gainor, Justin F., Heymach, John V., Lou, Yanyan, Wu, Jia, Zhang, Jianjun, Vokes, Natalie I.

“…The role of combination chemotherapy with immune checkpoint inhibitors (ICI) (ICI-chemo) over ICI monotherapy (ICI-mono) in non-small cell lung cancer (NSCLC)…”
Get full text

Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer by Ravi, Arvind, Hellmann, Matthew D., Arniella, Monica B., Holton, Mark, Freeman, Samuel S., Naranbhai, Vivek, Stewart, Chip, Leshchiner, Ignaty, Kim, Jaegil, Akiyama, Yo, Griffin, Aaron T., Vokes, Natalie I., Sakhi, Mustafa, Kamesan, Vashine, Rizvi, Hira, Ricciuti, Biagio, Forde, Patrick M., Anagnostou, Valsamo, Riess, Jonathan W., Gibbons, Don L., Pennell, Nathan A., Velcheti, Vamsidhar, Digumarthy, Subba R., Mino-Kenudson, Mari, Califano, Andrea, Heymach, John V., Herbst, Roy S., Brahmer, Julie R., Schalper, Kurt A., Velculescu, Victor E., Henick, Brian S., Rizvi, Naiyer, Jänne, Pasi A., Awad, Mark M., Chow, Andrew, Greenbaum, Benjamin D., Luksza, Marta, Shaw, Alice T., Wolchok, Jedd, Hacohen, Nir, Getz, Gad, Gainor, Justin F.

“…Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC). To expand our understanding of the molecular…”
Get full text

Tumor Evolution: A Problem of Histocompatibility by Vokes, Natalie I., Van Allen, Eliezer M.

“…In this issue of Cell, two articles show that tumor-specific changes in HLA-mediated antigen presentation affect tumor immunogenicity and may play a role in…”
Get full text

Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes by Heeke, Simon, Gay, Carl M, Estecio, Marcos R, Tran, Hai, Morris, Benjamin B, Zhang, Bingnan, Tang, Ximing, Raso, Maria Gabriela, Rocha, Pedro, Lai, Siqi, Arriola, Edurne, Hofman, Paul, Hofman, Veronique, Kopparapu, Prasad, Lovly, Christine M, Concannon, Kyle, De Sousa, Luana Guimaraes, Lewis, Whitney Elisabeth, Kondo, Kimie, Hu, Xin, Tanimoto, Azusa, Vokes, Natalie I, Nilsson, Monique B, Stewart, Allison, Jansen, Maarten, Horváth, Ildikó, Gaga, Mina, Panagoulias, Vasileios, Raviv, Yael, Frumkin, Danny, Wasserstrom, Adam, Shuali, Aharona, Schnabel, Catherine A, Xi, Yuanxin, Diao, Lixia, Wang, Qi, Zhang, Jianjun, Van Loo, Peter, Wang, Jing, Wistuba, Ignacio I, Byers, Lauren A, Heymach, John V

“…Small cell lung cancer (SCLC) is an aggressive malignancy composed of distinct transcriptional subtypes, but implementing subtyping in the clinic has remained…”
Get more information

The Role of Whole Exome Sequencing in Distinguishing Primary and Secondary Lung Cancers by Vokes, Natalie I, Zhang, Jianjun

“…Non-small cell lung cancer (NSCLC) that presents with multiple lung tumors (MLTs) poses a challenge to accurate staging and prognosis. MLTs that arise as…”
Get full text